-
IntroducedFeb 28, 2025
-
Passed House
-
Passed Senate
-
Signed into Law
Stem Cell Therapy; Authorizes licensed health care providers to perform stem cell therapy; specifies requirements for stem cells that may be used by such providers; requires such providers to adhere to applicable current good manufacturing practices in performance of such therapies; requires health care providers to provide specified written notice to patients before performing any stem cell therapy; specifies requirements for written notice; provides advertisement requirements; requires health care providers to obtain written consent from patient or his or her representative before performing therapy; specifies requirements for consent form; provides applicability; provides for disciplinary action; requires DOH to adopt rules.
Last Action See all actions
House • Apr 04, 2025: Now in Health & Human Services Committee
Latest Bill Text See all bill texts
Summary/Bill Text
Comments on HB 1617
Tweets
Whip Lists
Sponsors
- Health Professions & Programs Subcommitteeprimary
Votes
Actions
- Apr 04, 2025 | House
- Referred to Health & Human Services Committee
- Now in Health & Human Services Committee
- Apr 03, 2025 | House
- Favorable with CS by Health Professions & Programs Subcommittee
- Reported out of Health Professions & Programs Subcommittee
- Laid on Table under Rule 7.18(a)
- CS Filed
- 1st Reading (Committee Substitute 1)
- Apr 01, 2025 | House
- Added to Health Professions & Programs Subcommittee agenda
- Mar 05, 2025 | House
- Referred to Health Professions & Programs Subcommittee
- Referred to Health & Human Services Committee
- Now in Health Professions & Programs Subcommittee
- Mar 04, 2025 | House
- 1st Reading (Original Filed Version)
- Feb 28, 2025 | House
- Filed